Filed: 5/15/2026ACC: 0001104659-26-062464
📋 What this filing means
FORESITE CAPITAL MANAGEMENT V, LLC filed this quarterly 13F‑HR report disclosing 9 equity positions with a total reported market value of $271.00M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
9
Positions
$271.00M
Total AUM (reported)
10.29M
Total Shares
Allocation by class
COM$255.67M94.3%
COM CL A$15.32M5.7%
Portfolio Concentration
Top 3$221.78M81.8%
4–10$49.21M18.2%
Top 3 weight
81.8%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 10.29M
Sole
Full voting authority
10.29M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole9
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings9
Rows:
ALUMIS INC.
SOLEShares5.90M
TypeSH
Market value$129.91M
47.94%
Sole
5.90M
Shared
0.00
None
0.00
CG Oncology, Inc.
SOLEShares1M
TypeSH
Market value$67.95M
25.08%
Sole
1M
Shared
0.00
None
0.00
Disc Medicine, Inc.
SOLEShares374.07K
TypeSH
Market value$23.92M
8.83%
Sole
374.07K
Shared
0.00
None
0.00
Hims & Hers Health, Inc.
SOLEShares738.15K
TypeSH
Market value$15.32M
5.65%
Sole
738.15K
Shared
0.00
None
0.00
Eikon Therapeutics, Inc.
SOLEShares1.32M
TypeSH
Market value$13.95M
5.15%
Sole
1.32M
Shared
0.00
None
0.00
Lyell Immunopharma, Inc.
SOLEShares477.08K
TypeSH
Market value$9.57M
3.53%
Sole
477.08K
Shared
0.00
None
0.00
Pharvaris N.V.
SOLEShares194.13K
TypeSH
Market value$5.48M
2.02%
Sole
194.13K
Shared
0.00
None
0.00
Nurix Therapeutics, Inc.
SOLEShares265K
TypeSH
Market value$4.11M
1.52%
Sole
265K
Shared
0.00
None
0.00
Maze Therapeutics, Inc.
SOLEShares25.91K
TypeSH
Market value$773.3K
0.29%
Sole
25.91K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
ALUMIS INC.SOLE | COM | 5.90M | SH | $129.91M 47.94% | 5.90M | 0.00 | 0.00 |
CG Oncology, Inc.SOLE | COM | 1M | SH | $67.95M 25.08% | 1M | 0.00 | 0.00 |
Disc Medicine, Inc.SOLE | COM | 374.07K | SH | $23.92M 8.83% | 374.07K | 0.00 | 0.00 |
Hims & Hers Health, Inc.SOLE | COM CL A | 738.15K | SH | $15.32M 5.65% | 738.15K | 0.00 | 0.00 |
Eikon Therapeutics, Inc.SOLE | COM | 1.32M | SH | $13.95M 5.15% | 1.32M | 0.00 | 0.00 |
Lyell Immunopharma, Inc.SOLE | COM | 477.08K | SH | $9.57M 3.53% | 477.08K | 0.00 | 0.00 |
Pharvaris N.V.SOLE | COM | 194.13K | SH | $5.48M 2.02% | 194.13K | 0.00 | 0.00 |
Nurix Therapeutics, Inc.SOLE | COM | 265K | SH | $4.11M 1.52% | 265K | 0.00 | 0.00 |
Maze Therapeutics, Inc.SOLE | COM | 25.91K | SH | $773.3K 0.29% | 25.91K | 0.00 | 0.00 |